Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02). Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors. Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms. The Phase III multi-regional clinical trial...
2,800 Singapore Students to Benefit from new STEM Partnership
Year Long Programme with Science Centre Singapore to kick off on World DNA Day as part of Illumina's Future is Bright Initiative. SINGAPORE, April 25, 2023 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) today announced an inaugural partnership with the Science Centre Board to inspire 2,800 students through the power of genomics. ...
WARBURG PINCUS TO INVEST IN EVERISE AND PARTNER WITH BROOKFIELD FOR THE NEXT PHASE OF GROWTH
NEW YORK and SINGAPORE and MUMBAI, Oct. 3, 2023 /PRNewswire/ -- Everise, a leading global healthcare services outsourcing company, announced today that Warburg Pincus, a leading global growth investor, has agreed to invest in the company. Warburg Pincus joins existing investor Brookfield and both investors are committed to accelerating the growth trajectory...
Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer
SHANGHAI and SAN DIEGO, Nov. 24, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, today announced the recent appointment of Su Zhang, M.B.A., as the Chief Financial Officer (CFO). Su will have board responsibility across corporate and operational...
Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID
SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ -- Panacell Biotech Co., Ltd. said that NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness. Seung-Ho Choi, CEO of Panacell Biotech Panacell Biotech is South Korea's...
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology...
ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the results of two clinical studies of IBI311 (anti-IGF-1R monoclonal antibody),a Phase I trial in healthy subjects...
Stryker’s debut at World Intelligence Congress: Bringing Stryker’s Advanced Digital Healthcare to China
SHANGHAI, June 24, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), a leading medical technologies company, attended the 6th World Intelligence Congress (WIC) in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market. This is the first time for Stryker to participate in WIC as a strategic partner in healthcare industry, marking a significant...
WuXi Biologics Named to CDP Water Security “A List” for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 21, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it...
Study Shows Ubie Symptom Checker Accuracy Rivals Physicians, Outperforms Competitors In Providing Disease Information
Results show Ubie's differential diagnosis platform had a Top-5 hit accuracy of 63.4% and a Top-10 hit accuracy of 71.6%; median physician accuracy was 72.9% Ubie is effective in providing relevant information based on symptoms, making it valuable in speeding diagnosis and care delivery for improved outcomes The AI-assisted evaluation...
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond SHANGHAI, July 19, 2024 /PRNewswire/ -- Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and...
